GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » PB Ratio

PRTA (Prothena) PB Ratio : 1.40 (As of Dec. 12, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Prothena PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Prothena's share price is $13.87. Prothena's Book Value per Share for the quarter that ended in Sep. 2024 was $9.93. Hence, Prothena's PB Ratio of today is 1.40.

Good Sign:

Prothena Corp PLC stock PB Ratio (=1.42) is close to 5-year low of 1.31

The historical rank and industry rank for Prothena's PB Ratio or its related term are showing as below:

PRTA' s PB Ratio Range Over the Past 10 Years
Min: 0.91   Med: 3.37   Max: 12.01
Current: 1.4

During the past 13 years, Prothena's highest PB Ratio was 12.01. The lowest was 0.91. And the median was 3.37.

PRTA's PB Ratio is ranked better than
72.32% of 1279 companies
in the Biotechnology industry
Industry Median: 2.52 vs PRTA: 1.40

During the past 12 months, Prothena's average Book Value Per Share Growth Rate was -13.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 31.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 11.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -0.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Prothena was 31.40% per year. The lowest was -24.20% per year. And the median was 8.55% per year.

Back to Basics: PB Ratio


Prothena PB Ratio Historical Data

The historical data trend for Prothena's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena PB Ratio Chart

Prothena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.31 2.61 4.95 5.05 3.48

Prothena Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.19 3.48 2.65 1.91 1.68

Competitive Comparison of Prothena's PB Ratio

For the Biotechnology subindustry, Prothena's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's PB Ratio distribution charts can be found below:

* The bar in red indicates where Prothena's PB Ratio falls into.



Prothena PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Prothena's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=13.87/9.931
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Prothena  (NAS:PRTA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Prothena PB Ratio Related Terms

Thank you for viewing the detailed overview of Prothena's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena Business Description

Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Executives
Karin L Walker officer: See Remarks C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith officer: Chief Operating Officer C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp officer: Chief Regulatory Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek officer: Chief Legal Officer C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren officer: Chief Medical Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago officer: Chief Scientific Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe director 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen officer: Chief Financial Officer C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney officer: CSO & Head of R&D C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr. director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier director
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453